SL Family of WEB Aneurysm Embolization Devices

Officials from Sequent Medical Inc. announce that the company has received CE mark for the SL family of WEB Aneurysm Embolization Devices, and has commenced a controlled release of these new models in select neurovascular centers in Europe. The SL family offers a lower profile and superior navigability that will enable physicians to treat a broader range of aneurysms with the WEB platform.

The SL configurations are made possible by further advancement of Sequent Medical's proprietary MicroBraid technology, a dense mesh constructed from a large number of extremely fine Nitinol wires. Unlike conventional medical braids, MicroBraid features a mix of wire diameters and high wire counts to achieve a tailored balance of compliance, porosity, and profile across device sizes. 

The SL family consists of two separate product configurations, the WEB SL and WEB SLS, each with a distinct shape designed to accommodate varying aneurysm morphologies. Both configurations are available in multiple sizes ranging from 4mm to 11mm and are designed for delivery through Sequent Medical's VIA microcatheters.

The WEB SL and WEB SLS will build upon the growing experience with the original dual layer WEB, now referred to as the WEB DL configuration, which has now been used to treat over 280 ruptured and unruptured aneurysms in Europe and Latin America. 

"Sequent Medical has responded to physicians' requests in developing the WEB SL configurations," says Prof Laurent Pierot, MD PhD, Head of the Department of Radiology, Maison Blanche Hospital, Reims, France. "The SL family promises to expand the range of aneurysms physicians can treat with the WEB while continuing to offer the familiar straightforward procedure we've come to value with the WEB DL." 

"Combined with our recently introduced VIA microcatheter line, the introduction of the SL products demonstrates Sequent Medical's ongoing commitment to developing a broad portfolio of innovative catheter-based technologies for neurovascular specialists and their patients," states Tom Wilder, president and CEO.